store at low temperature
store at -80°C
Ravulizumab (ALXN1210) is a humanized monoclonal antibody targeting complement factor 5 that specifically binds to human complement protein C5 with high affinity to block complement activation. Ravulizumab can be used for the prevention and treatment of paroxysmal sleep hemoglobinuria, atypical hemolytic uremic syndrome and myasthenia gravis.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 372.00 | |
5 mg | In stock | $ 972.00 | |
10 mg | In stock | $ 1,530.00 | |
25 mg | In stock | $ 2,280.00 | |
50 mg | In stock | $ 2,970.00 | |
100 mg | In stock | $ 4,180.00 |
Description | Ravulizumab (ALXN1210) is a humanized monoclonal antibody targeting complement factor 5 that specifically binds to human complement protein C5 with high affinity to block complement activation. Ravulizumab can be used for the prevention and treatment of paroxysmal sleep hemoglobinuria, atypical hemolytic uremic syndrome and myasthenia gravis. |
In vitro | Binding to C5 with high affinity, Ravulizumab inhibits the formation of C5a and C5b, thereby preventing immune activation and hemolysis [1]. |
Synonyms | ALXN1210 |
Molecular Weight | N/A |
CAS No. | 1803171-55-2 |
store at low temperature
store at -80°C
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Ravulizumab 1803171-55-2 Immunology/Inflammation Complement System ALXN 1210 ALXN-1210 ALXN1210 inhibitor inhibit